Cowen to host conference call to discuss first quarter 2021 financial results on Thursday, April 29. Click here for more information.

reSET-ing the Treatment Paradigm for Mental Health | Corey McCann, MD, PhD, President and CEO, Pear Therapeutics

Insight by

Charles Rhyee, Health Care Technology Analyst speaks with Corey McCann, MD, PhD, President and CEO of Pear Therapeutics. Pear Therapeutics is a pioneer in prescription digital therapeutics. It is the first company to receive FDA market authorization for software to treat disease.

They discuss the impact of COVID-19 on mental health, the challenges of getting individuals treatment during the pandemic and how software can serve as front-line treatment for a wide range of conditions for the first time. This includes substance use disorder, opiate use disorder and chronic insomnia.

Their conversation delves into the advantages that a digital therapeutics platform has over traditional drug development. They also speak about the unique challenges and opportunities of launching a whole new class of drugs in this challenging period.

Press play to listen to their conversation.

Corey M. McCann, MD, PhD, President and CEO, Pear Therapeutics

Corey M. McCann, MD, PhD, is the President and CEO of Pear Therapeutics. Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies.

Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system expertise group, advising clients across the healthcare value chain.

Corey has previous investment experience with RiverVest Venture Partners and at NeuroInsights. Corey is also a co-founder, advisor, or Board Director at AgNovos Healthcare, Alcyone Lifesciences, Dragonfly Sciences, Edumedics, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health.

Corey trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He received his MD from Washington University in St. Louis.

Get the Full Report

If you’re already a member of our Research portal, log in.

Log In

If not, reach out to us directly for more information.

More Like This


The Right Way to Access Care | Rightway Healthcare CEO, Jordan Feldman

Read More

The Need for New Models of Primary Care | Scott Shreeve, Co-Founder & CEO, Crossover Health

Read More

The Outlook for Telehealth and Virtual Care at the Cleveland Clinic

Read More